Sai Parenteral's Ltd.

Use of Proceeds

Promoters

Promoter Shareholding

About the Company

Our Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. We are in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets. Our Company’s portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, we have capabilities in sterile manufacturing for critical care and penicillin-based therapies, offering delivery systems that include dry powder injections, pre-filled syringes, ampoules, and vials. We manufacture and sell Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market. We started our export business in Fiscal 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. We export our products to the Regulated and Semi-Regulated Markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors. Our Company’s CDMO business includes comprehensive solutions on product development, validation batches, stability studies, dossier compilation, international regulatory filings and commercial manufacturing. We believe that our R&D expertise and regulatory compliance capabilities positions us as a preferred CDMO partner for our customers in the Regulated and Semi-Regulated Markets. Our Company, through its wholly owned Singapore subsidiary, Sai Parenterals Pte. Limited, has entered into a Share Purchase Agreement dated September 23, 2025 with Noumed Life Sciences Limited (UK), Mark Thulborne, and Jo-maree Delac to acquire a 74.60% majority and controlling stake in Noumed, including an equity infusion of AUD 4.00 million as a primary in Noumed Pharmaceuticals Pte Ltd, Australia. Noumed Pharmaceuticals Pty Limited (“Noumed”), an Australia-based pharmaceutical company in the business of Intellectual Property (IP) dossier-led commercialisation, integrated supply chain management with long-standing partnerships with retail pharmacy networks in Australia. For further details, please see “Objects of the Offer – Investment in wholly owned subsidiary, Sai Parenterals Pte Limited